The development of sustained-release formulations for vaginal delivery of certain drugs has a big potential toward the increase of the treatment efficiency and patient compliance. One of the possible strategies to formulate sustained release dosage form for vaginal delivery is the incorporation of sustained-release microparticles into the bio-adhesive gel. Objectives of this study were to assess the possibility to formulate matrix system microparticles for vaginal delivery using lipid-based excipient SyncrowaxTM HGLC and optionally Gelucire® 50/13 (G-50/13), Avicel® PH-101 (MCC) or hypromellose type K100M excipients. As model drugs for this purpose were chosen antiretroviral zidovudine (known as azidothymidine; AZT) and antimicrobial metronidazole (MTZ).
|Publication status||Published - 11 May 2021|
|Event||12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology (delayed due to COVID19) - |
Duration: 11 May 2021 → 14 May 2021
|Conference||12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology (delayed due to COVID19)|
|Period||11/05/2021 → 14/05/2021|